shire plc (SHP:London)
Transactions by SHIRE PLC (SHP) in the last 6 months
The shareholders of Shire plc (LSE:SHP) authorized a share repurchase program at its Annual General Meeting on April 30, 2013. Under the program, the company will repurchase up to 55,741,587 ordinary shares, representing 10% of the issued share capital. The minimum price, which may be paid for an ordinary share is 5 pence. The maximum price, which may be paid for an ordinary share shall be the higher of an amount equal to 105% of the average of the middle market quotations ...
Shire plc (LSE:SHP) agreed to acquire SARcode Bioscience, Inc. from Clarus Lifesciences I, L.P., a fund of Clarus Ventures, LLC, Sofinnova Ventures, Inc. and other investors for approximately $160 million on March 25, 2013. SARcode shareholders will also be eligible to receive additional undisclosed payments upon achievement of certain clinical, regulatory, and/or commercial milestones. The transaction is subject to regulatory approval in the United States, and other ...
Clarus Lifesciences I, L.P.
Clarus Ventures, LLC
Rho Capital Partners, Inc.
Sofinnova Ventures, Inc.
Shire plc (LSE:SHP) signed an agreement to acquire Lotus Tissue Repair, Inc. from Third Rock Ventures, LLC and other investors on January 8, 2013. Shire will purchase Lotus Tissue for an upfront payment and certain contingent payments based on the achievement of certain safety and development milestones. The transaction is subject to customary government approvals. William J. Chudd, Brian Wolfe, Ashley M. Bryant, Kyoko Takahashi Lin, Andrew Blau, Jessica Lutrin, Frank ...
|Actavis Inc||$125.50 USD||+1.89|
|Forest Laboratories Inc||$38.53 USD||-0.17|
|Mylan Inc/PA||$31.40 USD||+0.70|
|UCB SA||€44.45 EUR||-0.55|
|Valeant Pharmaceuticals International Inc||C$80.42 CAD||+3.24|
|View Industry Companies|